QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Reslizumab Classification, Mechanism, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Reslizumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why should rechallenge with reslizumab not be treated as a routine diagnostic test after a suspected serious hypersensitivity reaction?

Rechallenge is always required to establish causality Rechallenge may expose the patient to unacceptable risk and should be considered only when clinically appropriate in routine care Rechallenge has no evidentiary value under any circumstances Rechallenge eliminates the need to document the original reaction

Question 2 of 10 Which case information is most important when evaluating whether an asthma exacerbation represents treatment failure?

Only the preferred term selected for the event Baseline control, exacerbation history, inhaler adherence, corticosteroid changes, dosing chronology, triggers and alternative diagnoses Only the product batch number The patient's sex without clinical or treatment information

Question 3 of 10 A patient receiving reslizumab develops worsening dyspnoea and fever several days after an infusion. Which approach is most appropriate?

Classify the event automatically as anaphylaxis because dyspnoea occurred after treatment Assess asthma control, infection evidence, infusion chronology, objective findings and other pulmonary causes before assigning causality Assume the event is unrelated because it did not begin during the infusion Use the patient's eosinophil count alone to determine the diagnosis

Question 4 of 10 Which quality measure best evaluates whether follow-up activity is effective?

The number of follow-up requests sent, regardless of their content or outcome Whether relevant information was obtained, evaluated and incorporated into the case assessment The number of standard templates used without medical review Whether every case received an identical follow-up questionnaire

Question 5 of 10 Which statement best expresses the regulatory meaning of a detected safety signal?

A signal is proof that the medicine causes the event A signal is a hypothesis requiring further evaluation using clinical, epidemiological, product and alternative-cause evidence A signal can be confirmed solely by a single serious case A signal is irrelevant unless every case has positive rechallenge

Question 6 of 10 Which stratification would be most relevant when assessing reports of asthma exacerbation during reslizumab treatment?

Indication, disease severity, treatment phase, duration, combination therapy and baseline risk factors Only the alphabetical order of reporter names Only the total number of reports without an exposure denominator The colour of the administration room and unrelated product marketing data

Question 7 of 10 Which statement best reflects the article's overall approach to reslizumab pharmacovigilance?

Mechanism alone is sufficient to determine causality Pharmacovigilance should be mechanism-led but integrate disease context, host susceptibility, treatment chronology, objective evidence and competing explanations Only labelled events should be investigated All respiratory events during treatment should be grouped as one immune-mediated category

Question 8 of 10 Which documentation approach best supports inspection-ready source-to-decision traceability for a reslizumab case?

Record only the final causality category and omit the underlying reasoning Preserve source information, exposure chronology, objective findings, competing causes, follow-up, medical review and the basis for the final conclusion Rely on verbal discussions that are not documented Store the event term separately from all treatment and clinical information

Question 9 of 10 What is the most appropriate interpretation of reslizumab's IL-5 mechanism in a safety assessment?

Any infection reported during treatment should be considered caused by IL-5 blockade The mechanism provides a safety hypothesis involving eosinophil biology, but causality still requires clinical, temporal and alternative-cause assessment IL-5 neutralisation proves that respiratory symptoms cannot be caused by asthma The mechanism is relevant only to efficacy and has no value in pharmacovigilance

Question 10 of 10 A periodic review compares pre-authorisation and post-authorisation reports of infection but does not account for changes in indication or treated population. What is the principal limitation?

The review is automatically invalid because post-authorisation data cannot be used Differences in population, exposure, treatment phase and clinical use may create apparent changes unrelated to a true change in risk Pre-authorisation data are always more reliable than post-authorisation data Indication has no effect on safety interpretation

QPPV.com

Knowledge Assessment: Reslizumab Classification, Mechanism, Safety and Pharmacovigilance

Cookie Settings